Replies to post #2331 on Enanta Pharmaceuticals Inc (ENTA)

[vinmantoo]

ENTA starts phase-2 trial of EDP-235 in non-hospitalized, standard-risk COVID patients:......Data are expected in 1H23. I had been hoping for a pivotal phase-2/3 trial. but either ENTA or the FDA evidently didn’t like that idea.

I was hoping the same. Maybe ENTA decided they didn't have the experience to run a phase 3 or they didn't want to risk the money. If the phase 2 data is good they will seek a partnership. Hell, they may have an interested suitor waiting in the wings to see what happens.